NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs, reported financial results for its fiscal year ended June 30, 2026, and provided an update on its clinical and regulatory progress. The company highlighted advancements for its lead candidate NV-387, including regulatory approval in the Democratic Republic of Congo to initiate Phase II trials for the treatment of Mpox and Ebola. Both trials began enrolling patients at the end of September 2026, marking a significant step forward for the company's pipeline.
In addition to the international trial approvals, NanoViricides received two key designations from the U.S. Food and Drug Administration for NV-387 as a treatment for measles: Orphan Drug Designation and Rare Pediatric Disease Drug designation. These designations are intended to incentivize the development of therapies for rare and serious conditions, and they underscore the potential of NV-387 to address multiple unmet medical needs.
Financially, the company reported approximately $2.79 million in cash and cash equivalents as of June 30, 2026, up from approximately $1.67 million a year earlier. During fiscal 2026, NanoViricides raised approximately $9.01 million through registered direct and at-the-market equity offerings. Subsequent to the fiscal year-end, in July, the company raised an additional $3.8 million and stated it is pursuing further funding through grants, contracts, partnerships, and debt or equity financing.
NanoViricides is focused on developing its novel nanoviricide(TM) class of drug candidates, which are based on intellectual property and technology licensed from TheraCour Pharma, Inc. The company's business model centers on licensing technology for specific antiviral applications. Its lead drug candidate, NV-387, is being developed as a broad-spectrum antiviral for respiratory viral infections such as RSV, COVID-19, Long COVID, and influenza, as well as for MPOX/Smallpox and measles. Another advanced candidate, NV-HHV-1, is in development for the treatment of Shingles.
According to the company, NV-387 is a nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir, while a separate candidate, NV-CoV-2-R, combines NV-387 with remdesivir encapsulated within its polymeric micelles. The company believes that since remdesivir is already FDA-approved, its drug candidate encapsulating remdesivir is likely to be approvable if safety is comparable. Remdesivir is developed by Gilead, and NanoViricides has developed both NV-CoV-2 and NV-CoV-2-R independently.
The company is also pursuing drugs against a range of viral diseases, including oral and genital herpes, viral diseases of the eye such as EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola. The platform technology and programs are based on the TheraCour nanomedicine technology, which NanoViricides licenses exclusively and perpetually for several human viral diseases, including HIV/AIDS, hepatitis B and C, rabies, herpes simplex, varicella-zoster, influenza, dengue, Japanese encephalitis, West Nile, Ebola/Marburg, and certain coronaviruses.
For investors, the latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. The full press release can be viewed at https://ibn.fm/s000r. More information about the company is available at www.nanoviricides.com.
This news matters because it demonstrates tangible progress in the clinical development of a novel antiviral platform that could potentially address multiple high-priority infectious diseases. If successful, NV-387 could provide a new therapeutic option for outbreaks of Mpox and Ebola, as well as for measles, a disease that has seen resurgences in various parts of the world. The FDA designations for measles highlight the unmet need in this area and could expedite development and review. For the industry, NanoViricides' broad-spectrum approach represents an innovative strategy that, if validated, could lead to treatments for a wide array of viral infections.
The financial updates indicate that the company has been able to raise capital to fund its operations and clinical trials, but it continues to seek additional funding to support its pipeline. The ability to secure financing will be critical as the company advances NV-387 through Phase II trials and pursues other programs.
MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MissionIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public.
